Table 1.
Metronidazole | Secnidazole | |
---|---|---|
n = 287 | n = 290 | |
% (n) | % (n) | |
Nonrespect of scheduled visits | 4.9 (14) | 3.8 (11) |
Nonevaluability of primary efficacy endpoint | 4.5 (13) | 1.7 (5) |
Concomitant antibiotic treatment | 3.5 (10) | 2.1 (6) |
Nonrespect of compliance | 2.4 (7) | 1.4 (4) |
of which missing data on compliance | 1.4 (4) | 1.4 (4) |
Error in randomisation | 1.4 (4) | 1.4 (4) |
Treatment initiated more than 3 days after randomisation | 1.0 (3) | 0 (0) |
Nonrespect of inclusion criteria | 0.3 (1) | 0.7 (2) |
Vaginal treatment | 0 (0) | 0.7 (2) |
Nonrespect of exclusion criteria | 0 (0) | 0.3 (1) |